###
中国临床研究:2023,36(4):487-491
本文二维码信息
码上扫一扫!
重症哮喘的治疗进展
(南京医科大学第一附属医院呼吸与危重症医学科,江苏 南京 210029)
Advances in research on treatment of severe asthma
(Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital with Nanjing Medical University, Nangjing, Jiangsu 210029, China)
摘要
本文已被:浏览 584次   下载 397
投稿时间:2023-03-03   网络发布日期:2023-04-20
中文摘要: 重症哮喘在所有哮喘患者中仅占一小部分,但却是其致残、致死的主要原因,给社会带来沉重的社会及经济负担。重症哮喘通常需要给予高剂量吸入皮质激素(ICS)和口服糖皮质激素治疗,上述治疗方法长期大量使用可引起一系列副作用。近年来,生物靶向治疗、支气管热成形术等新疗法不断发展,本文聚焦于重症哮喘治疗的现状及前景,以期为重症哮喘患者的个体化治疗提供参考依据。
Abstract:Severe asthma accounts for only a small proportion of all asthmatic patients, but its the main cause of disability and death of them, and brings heavy social and economic burden to the society. Severe asthma usually requires high-dose inhaled corticosteroid(ICS) and oral corticosteroids, which can cause a series of side effects. In recent years, new therapies such as biotargeted therapy and bronchial thermoplasty have continued to develop. This review summarizes status and prospects in treatment of severe asthma, aiming to provide a reference for personalized treatment and improvement of quality of life in severe asthma patients.
文章编号:     中图分类号:R562.2+5    文献标志码:A
基金项目:
引用文本:
郭秦星, 刘婉莹, 姚欣.重症哮喘的治疗进展[J].中国临床研究,2023,36(4):487-491.

用微信扫一扫

用微信扫一扫